Twist Bioscience CORP Form 4 insider transactions

NASDAQ
CEO Emily Leproust sold shares of Twist Bioscience to cover tax withholding obligations related to vesting Restricted Stock Units.
NASDAQ
Patrick John Finn, President and COO of Twist Bioscience, sold 6,865 shares of common stock on October 2, 2024, to cover tax withholding obligations related to vesting restricted stock units.
NASDAQ
Dennis Cho, Senior Vice President, Chief Legal Officer & Corporate Secretary of Twist Bioscience Corp, sold shares to cover tax withholding obligations related to the vesting of Restricted Stock Units.
NASDAQ
Dennis Cho, a Senior Vice President at Twist Bioscience, sold 234 shares of common stock to cover tax withholding obligations related to the vesting of Restricted Stock Units.
NASDAQ
Paula Green, SVP of Human Resources at Twist Bioscience, sold 297 shares of common stock on September 20, 2024, to cover tax withholding obligations related to vesting Restricted Stock Units.
NASDAQ
CEO of Twist Bioscience, Emily Leproust, sold 1,730 shares of common stock on September 20, 2024, to cover tax withholding obligations related to vesting Restricted Stock Units.
NASDAQ
Dennis Cho, a Senior Vice President at Twist Bioscience Corp, sold shares to cover tax withholding obligations related to the vesting of Restricted Stock Units.
NASDAQ
Dennis Cho, a Senior Vice President at Twist Bioscience, sold 275 shares of common stock to cover tax withholding obligations related to the vesting of Restricted Stock Units.
NASDAQ
Paula Green, SVP of Human Resources at Twist Bioscience, reports selling 912 shares of common stock to cover tax withholding obligations related to vesting Restricted Stock Units.
NASDAQ
Robert F. Werner, Chief Accounting Officer of Twist Bioscience, sold 240 shares of common stock to cover tax withholding obligations related to vesting Restricted Stock Units.
NASDAQ
Emily Leproust, CEO of Twist Bioscience, sold 2,340 shares of common stock on September 6, 2024, to cover tax withholding obligations related to the vesting of Restricted Stock Units.
NASDAQ
Robert F. Werner, Chief Accounting Officer of Twist Bioscience Corp, reports the sale of 813 shares of common stock on August 23, 2024, to cover tax withholding obligations related to vesting Restricted Stock Units.
NASDAQ
Dennis Cho, a Senior Vice President at Twist Bioscience, sold 709 shares of common stock on August 5, 2024, to cover tax withholding obligations related to vesting Restricted Stock Units.
NASDAQ
Patrick John Finn, COO of Twist Bioscience, sold 2,885 shares of common stock on August 5, 2024, to cover tax withholding obligations related to the vesting of Restricted Stock Units.
NASDAQ
Twist Bioscience CEO Emily Leproust sold 5,139 shares of common stock on August 5, 2024, to cover tax withholding obligations related to the vesting of restricted stock units.
NASDAQ
Paula Green, SVP of Human Resources at Twist Bioscience, sold 1,137 shares of common stock on August 5, 2024, to cover tax withholding obligations related to vesting restricted stock units.
NASDAQ
Robert F. Werner, Chief Accounting Officer of Twist Bioscience Corp, sold 168 shares of common stock to cover tax withholding obligations related to vesting Restricted Stock Units.
NASDAQ
Patrick John Finn, President and COO of Twist Bioscience, sold 2,207 shares of common stock to cover tax withholding obligations related to the vesting of Restricted Stock Units.
NASDAQ
Adam Laponis, CFO of Twist Bioscience, sold 842 shares of common stock on July 9, 2024, to cover tax withholding obligations related to the vesting of Restricted Stock Units.
NASDAQ
Dennis Cho, a Senior Vice President at Twist Bioscience, sold 126 shares of common stock on July 2, 2024, at a price of $48.002 per share to cover tax withholding obligations related to the vesting of Restricted Stock Units.
NASDAQ
Emily Leproust, CEO of Twist Bioscience, sold 1,114 shares of common stock to cover tax withholding obligations related to vesting Restricted Stock Units.
NASDAQ
Paula Green, SVP of Human Resources at Twist Bioscience, sold 322 shares of common stock on July 2, 2024, to cover tax withholding obligations related to the vesting of Restricted Stock Units.
NASDAQ
Patrick John Finn, COO of Twist Bioscience, sold 476 shares of common stock on July 2, 2024, to cover tax withholding obligations related to vesting restricted stock units.
NASDAQ
Emily Leproust, CEO of Twist Bioscience, sold 1,732 shares of common stock on June 20, 2024, to cover tax withholding obligations related to the vesting of Restricted Stock Units.
NASDAQ
Paula Green, SVP of Human Resources at Twist Bioscience, sold 297 shares of common stock on June 20, 2024, to cover tax withholding obligations related to the vesting of Restricted Stock Units.
NASDAQ
Dennis Cho, a Senior Vice President at Twist Bioscience Corp, sold 234 shares of common stock on June 20, 2024, to cover tax withholding obligations related to the vesting of Restricted Stock Units.
NASDAQ
Dennis Cho, a Senior Vice President at Twist Bioscience Corp, sold 95 shares of common stock on June 14, 2024, to cover tax withholding obligations related to the vesting of Restricted Stock Units.
NASDAQ
Dennis Cho, a Senior Vice President at Twist Bioscience, sold 276 shares of common stock to cover tax withholding obligations related to the vesting of Restricted Stock Units.
NASDAQ
Robert F. Werner, Chief Accounting Officer of Twist Bioscience Corp, sold 242 shares of common stock on June 6, 2024, to cover tax withholding obligations related to the vesting of Restricted Stock Units.
NASDAQ
Paula Green, SVP of Human Resources at Twist Bioscience, sold 918 shares of common stock on June 6, 2024, at a price of $51.329 per share to cover tax withholding obligations related to vesting Restricted Stock Units.